Denali Therapeutics Inc. Proceeds from Sale and Maturity of Marketable Securities
Denali Therapeutics Inc. (DNLI) reported Proceeds from Sale and Maturity of Marketable Securities of $417.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-06
- Denali Therapeutics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $197.03M, a 21.46% increase year-over-year.
- Denali Therapeutics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $220.00M, a 36.01% increase year-over-year.
- Denali Therapeutics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $275.00M, a 21.65% decline year-over-year.
- Denali Therapeutics Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $107.08M, a 45.92% decline year-over-year.
- Denali Therapeutics Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $706.05M, a 38.98% decline from fiscal 2024.
- Denali Therapeutics Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $1.16B, a 44.26% decline from fiscal 2023.
- Denali Therapeutics Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $2.08B, a 109.38% increase from fiscal 2022.
- Denali Therapeutics Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $991.49M, a 29.67% decline from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $197.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $417.03M 10-Q · filed 2026-08-06 | $692.03M derived: sum of 3 quarters · filed 2026-08-06 | $799.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $220.00M 10-Q · filed 2026-05-07 | $495.00M derived: sum of 2 quarters · filed 2026-05-07 | $602.08M derived: sum of 3 quarters · filed 2026-05-07 | $764.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $275.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $382.08M derived: sum of 2 quarters · filed 2026-02-26 | $544.29M derived: sum of 3 quarters · filed 2026-08-06 | $706.05M 10-K · filed 2026-02-26 |
| 2025-09-30 | $107.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $269.29M derived: sum of 2 quarters · filed 2026-08-06 | $431.05M 10-Q · filed 2025-11-06 | $782.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $162.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $323.96M 10-Q · filed 2026-08-06 | $674.97M derived: sum of 3 quarters · filed 2026-08-06 | $872.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $161.75M 10-Q · filed 2026-05-07 | $512.75M derived: sum of 2 quarters · filed 2026-05-07 | $710.75M derived: sum of 3 quarters · filed 2026-05-07 | $935.75M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $351.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $549.00M derived: sum of 2 quarters · filed 2026-02-26 | $774.00M derived: sum of 3 quarters · filed 2026-02-26 | $1.16B 10-K · filed 2026-02-26 |
| 2024-09-30 | $198.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $423.00M derived: sum of 2 quarters · filed 2025-11-06 | $806.12M 10-Q · filed 2025-11-06 | $1.30B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $225.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $608.12M 10-Q · filed 2025-08-11 | $1.10B derived: sum of 3 quarters · filed 2026-02-26 | $1.70B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $383.12M 10-Q · filed 2025-05-06 | $872.12M derived: sum of 2 quarters · filed 2026-02-26 | $1.47B derived: sum of 3 quarters · filed 2026-02-26 | $2.03B derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $489.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.09B derived: sum of 2 quarters · filed 2026-02-26 | $1.64B derived: sum of 3 quarters · filed 2026-02-26 | $2.08B 10-K · filed 2026-02-26 |
| 2023-09-30 | $601.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.15B derived: sum of 2 quarters · filed 2024-11-06 | $1.59B 10-Q · filed 2024-11-06 | $1.95B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $552.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $985.83M 10-Q · filed 2024-08-01 | $1.35B derived: sum of 3 quarters · filed 2025-02-27 | $1.49B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $433.79M 10-Q · filed 2024-05-07 | $797.78M derived: sum of 2 quarters · filed 2025-02-27 | $942.12M derived: sum of 3 quarters · filed 2025-02-27 | $1.17B derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $364.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $508.34M derived: sum of 2 quarters · filed 2025-02-27 | $740.99M derived: sum of 3 quarters · filed 2025-02-27 | $991.49M 10-K · filed 2025-02-27 |
| 2022-09-30 | $144.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $376.99M derived: sum of 2 quarters · filed 2023-11-07 | $627.49M 10-Q · filed 2023-11-07 | $821.24M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $232.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $483.15M 10-Q · filed 2023-08-08 | $676.90M derived: sum of 3 quarters · filed 2024-02-28 | $969.96M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $250.50M 10-Q · filed 2023-05-08 | $444.25M derived: sum of 2 quarters · filed 2024-02-28 | $737.31M derived: sum of 3 quarters · filed 2024-02-28 | $1.22B derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $193.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $486.81M derived: sum of 2 quarters · filed 2024-02-28 | $969.31M derived: sum of 3 quarters · filed 2024-02-28 | $1.41B 10-K · filed 2024-02-28 |
| 2021-09-30 | $293.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $775.56M derived: sum of 2 quarters · filed 2022-11-03 | $1.22B 10-Q · filed 2022-11-03 | $1.45B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $482.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $923.00M 10-Q · filed 2022-08-08 | $1.15B derived: sum of 3 quarters · filed 2023-02-27 | $1.31B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $440.50M 10-Q · filed 2022-05-05 | $672.30M derived: sum of 2 quarters · filed 2023-02-27 | $824.80M derived: sum of 3 quarters · filed 2023-02-27 | $965.16M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $231.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $384.30M derived: sum of 2 quarters · filed 2023-02-27 | $524.66M derived: sum of 3 quarters · filed 2023-02-27 | $665.36M 10-K · filed 2023-02-27 |
| 2020-09-30 | $152.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $292.86M derived: sum of 2 quarters · filed 2021-11-04 | $433.56M 10-Q · filed 2021-11-04 | $629.27M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $140.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $281.06M 10-Q · filed 2021-08-04 | $476.77M derived: sum of 3 quarters · filed 2022-02-28 | $604.22M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $140.70M 10-Q · filed 2021-05-05 | $336.42M derived: sum of 2 quarters · filed 2022-02-28 | $463.87M derived: sum of 3 quarters · filed 2022-02-28 | $572.24M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $195.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $323.17M derived: sum of 2 quarters · filed 2022-02-28 | $431.54M derived: sum of 3 quarters · filed 2022-02-28 | $535.33M 10-K · filed 2022-02-28 |
| 2019-09-30 | $127.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $235.82M derived: sum of 2 quarters · filed 2020-11-05 | $339.61M 10-Q · filed 2020-11-05 | $436.94M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $108.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $212.16M 10-Q · filed 2020-08-07 | $309.49M derived: sum of 3 quarters · filed 2021-02-26 | $394.01M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $103.79M 10-Q · filed 2020-05-07 | $201.12M derived: sum of 2 quarters · filed 2021-02-26 | $285.64M derived: sum of 3 quarters · filed 2021-02-26 | $350.39M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $97.33M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $181.85M derived: sum of 2 quarters · filed 2021-02-26 | $246.60M derived: sum of 3 quarters · filed 2021-02-26 | $273.90M 10-K · filed 2021-02-26 |
| 2018-09-30 | $84.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $149.28M derived: sum of 2 quarters · filed 2019-11-06 | $176.57M 10-Q · filed 2019-11-06 | $215.63M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $64.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $92.05M 10-Q · filed 2019-08-06 | $131.11M derived: sum of 3 quarters · filed 2020-02-27 | $166.50M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $27.30M 10-Q · filed 2019-05-08 | $66.36M derived: sum of 2 quarters · filed 2020-02-27 | $101.75M derived: sum of 3 quarters · filed 2020-02-27 | $135.60M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $39.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $74.45M derived: sum of 2 quarters · filed 2020-02-27 | $108.30M derived: sum of 3 quarters · filed 2020-02-27 | $141.50M 10-K · filed 2020-02-27 |
| 2017-09-30 | $35.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $69.24M derived: sum of 2 quarters · filed 2018-11-08 | $102.44M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $33.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $67.05M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $33.20M 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $14.00M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |